Mar 11, 2025 8:30 am EDT Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
Mar 4, 2025 8:30 am EST Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
Feb 6, 2025 8:30 am EST Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
Feb 5, 2025 9:15 am EST Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
Jan 30, 2025 8:30 am EST Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
Dec 10, 2024 8:00 am EST Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
Dec 6, 2024 9:00 am EST VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
